These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19629383)

  • 1. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.
    Dalhoff A; Ambrose PG; Mouton JW
    Infection; 2009 Aug; 37(4):296-305. PubMed ID: 19629383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.
    Mouton JW; Brown DF; Apfalter P; Cantón R; Giske CG; Ivanova M; MacGowan AP; Rodloff A; Soussy CJ; Steinbakk M; Kahlmeter G
    Clin Microbiol Infect; 2012 Mar; 18(3):E37-45. PubMed ID: 22264314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antimicrobial susceptibility testing of bacteria isolated from animals: considerations concerning the predefinition of breakpoints from the clinical pharmacological viewpoint].
    Kietzmann M; Böttner A; Hafez HM; Kehrenberg C; Klarmann D; Krabisch P; Kühn T; Luhofer G; Richter A; Schwarz S; Traeder W; Waldmann KH; Wallmann J; Werckenthin C; ;
    Berl Munch Tierarztl Wochenschr; 2004; 117(3-4):81-7. PubMed ID: 15046455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance.
    Ringertz S; Olsson-Liljequist B; Kahlmeter G; Kronvall G
    Scand J Infect Dis Suppl; 1997; 105():8-12. PubMed ID: 9435026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European standards for antibiotic susceptibility testing: towards a theoretical consensus.
    Baquero F
    Eur J Clin Microbiol Infect Dis; 1990 Jul; 9(7):492-5. PubMed ID: 2226478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who defines resistance? The clinical and economic impact of antimicrobial susceptibility testing breakpoints.
    Jorgensen JH
    Semin Pediatr Infect Dis; 2004 Apr; 15(2):105-8. PubMed ID: 15185194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.
    MacGowan AP; Wise R
    J Antimicrob Chemother; 2001 Jul; 48 Suppl 1():17-28. PubMed ID: 11420334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BSAC standardized disc susceptibility testing method (version 10).
    Andrews JM; Howe RA;
    J Antimicrob Chemother; 2011 Dec; 66(12):2726-57. PubMed ID: 21921076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility.
    Brown D; Macgowan A
    J Antimicrob Chemother; 2010 Feb; 65(2):183-5. PubMed ID: 19996143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2014 Garrod Lecture: EUCAST - are we heading towards international agreement?
    Kahlmeter G
    J Antimicrob Chemother; 2015 Sep; 70(9):2427-39. PubMed ID: 26089441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints.
    Ambrose PG
    Treat Respir Med; 2005; 4 Suppl 1():5-11. PubMed ID: 15846151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining antibiotic resistance-towards international harmonization.
    Kahlmeter G
    Ups J Med Sci; 2014 May; 119(2):78-86. PubMed ID: 24836050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens.
    Jones RN; Stilwell MG; Wilson ML; Mendes RE
    Diagn Microbiol Infect Dis; 2013 May; 76(1):69-72. PubMed ID: 23490012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Setting and revising antibacterial susceptibility breakpoints.
    Turnidge J; Paterson DL
    Clin Microbiol Rev; 2007 Jul; 20(3):391-408, table of contents. PubMed ID: 17630331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibacterial spectrum of an antibiotic and clinical categorization].
    Cavallo JD; Mérens A
    Pathol Biol (Paris); 2008 Jul; 56(5):300-4. PubMed ID: 18178037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial Susceptibility of Pathogenic Gram-positive Anaerobic Cocci: Data of a University Hospital in Turkey].
    Akgül Ö; Söyletir G; Ülger Toprak N
    Mikrobiyol Bul; 2020 Jul; 54(3):404-417. PubMed ID: 32755517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Campylobacter and fluoroquinolones: a bias data set?
    Silley P
    Environ Microbiol; 2003 Apr; 5(4):219-30. PubMed ID: 12662169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.